NCT02208063View on ClinicalTrials.gov

A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial

PHASE3TerminatedINTERVENTIONAL
Enrollment

121

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

April 12, 2018

Study Completion Date

April 12, 2018

Conditions
Bacteremia
Interventions
DRUG

Telavancin

DRUG

Vancomycin

DRUG

Daptomycin

DRUG

Synthetic penicillin

DRUG

Cefazolin

Trial Locations (1)

43215

Remington-Davis Clinical Research, Columbus

Sponsors
All Listed Sponsors
lead

Cumberland Pharmaceuticals

INDUSTRY

NCT02208063 - A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial | Biotech Hunter | Biotech Hunter